Back

Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial

1 September 2025 (14:03 - 14:22)
Organised by: Logo
Congress Presentation Part of: Atherosclerosis: prevention and new regression Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Yu Jie Zhou

Beijing AnZhen Hospital affiliated to Capital Medical University, Beijing (China)

2 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on atherosclerotic plaque regression
Professor L. Badimon (Barcelona, ES)
Slides
Presentation thumbnail
Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial
Associate Professor M. Chan (Singapore, SG)
Abstract Slides

Access the full session

Session thumbnail
Atherosclerosis: prevention and new regression
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 14:03 CET
You may be interested in
thumbnail
Congress Presentation
Comparing coronary artery plaque regression in patients treated with ezetimibe or PCSK9 inhibitors following acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources